Keith C. Kummerfeld - 14 Jul 2023 Form 4 Insider Report for Arcturus Therapeutics Holdings Inc. (ARCT)

Role
Senior Vice President of Finance (Principal Accounting Officer)
Signature
/s/ Ilan Katz, attorney-in-fact
Issuer symbol
ARCT
Transactions as of
14 Jul 2023
Net transactions value
-$181,472
Form type
4
Filing time
18 Jul 2023, 18:50:25 UTC
Previous filing
19 Apr 2023
Next filing
19 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARCT Common Stock Options Exercise $40,680 +4,500 +474% $9.04 5,450 14 Jul 2023 Direct
transaction ARCT Common Stock Options Exercise $7,171 +1,437 +26% $4.99 6,887 14 Jul 2023 Direct
transaction ARCT Common Stock Options Exercise $14,558 +1,031 +15% $14.12 7,918 14 Jul 2023 Direct
transaction ARCT Common Stock Sale $243,880 -6,968 -88% $35.00 950 14 Jul 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARCT Employee Stock Option (right to buy) Options Exercise $0 -4,500 -18% $0.000000 21,000 14 Jul 2023 Common Stock 4,500 $9.04 Direct F3
transaction ARCT Employee Stock Option (right to buy) Options Exercise $0 -1,437 -17% $0.000000 7,126 14 Jul 2023 Common Stock 1,437 $4.99 Direct F3
transaction ARCT Employee Stock Option (right to buy) Options Exercise $0 -1,031 -11% $0.000000 7,938 14 Jul 2023 Common Stock 1,031 $14.12 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold pursuant to the Reporting Person's written trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 These shares were sold in multiple transactions, each at a price of $35.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by it on July 14, 2023.
F3 25% of the shares underlying the options vest on the one year anniversary of the date of grant, with the remainder vesting in 36 successive equal monthly increments thereafter.

Remarks:

Senior Vice President of Finance (Principal Accounting Officer)